Compare THM & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THM | KMDA |
|---|---|---|
| Founded | 1978 | 1990 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 402.9M | 460.3M |
| IPO Year | 2002 | 2013 |
| Metric | THM | KMDA |
|---|---|---|
| Price | $1.24 | $8.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.75 |
| AVG Volume (30 Days) | ★ 1.6M | 103.5K |
| Earning Date | 11-10-2026 | 11-09-2026 |
| Dividend Yield | N/A | ★ 6.86% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $12.75 |
| Revenue Next Year | N/A | $13.63 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.07 | $6.60 |
| 52 Week High | $3.65 | $9.35 |
| Indicator | THM | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 30.30 | 56.33 |
| Support Level | $1.07 | $7.99 |
| Resistance Level | $2.88 | $8.62 |
| Average True Range (ATR) | 0.19 | 0.25 |
| MACD | -0.03 | 0.09 |
| Stochastic Oscillator | 15.66 | 86.71 |
International Tower Hill Mines Ltd is a mining company. It is engaged in the acquisition, exploration, and development of mineral properties. The company holds interests in an exploration project, namely the Livengood Gold Project. It is located in the northwest of Fairbanks, Alaska, in the Tolovana mining district within the Tintina gold belt. The project property consists of land leased from the Alaska Mental Health Trust, several smaller private mineral leases, Alaska state mining claims purchased or located by the company, and the patented ground held by the company.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.